

products is less than or equal to about 2.0 % by weight.

43) (New) The solid composition of claim 42 wherein the two pharmaceutically acceptable antioxidants are edetate disodium and citric acid.

44) (New) A solid composition comprising (a) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable excipient and (b) a sustained release second layer comprising an effective amount of pseudoephedrine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable sustained release agent wherein the total amount of desloratadine degradation products is less than about 2.0%.

45) (New) A solid composition comprising (1) an immediate release first layer comprising about 2.5 mg of desloratadine and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant; and (2) a sustained release second layer comprising about 120 mg of pseudoephedrine or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable excipient.

46) (New) The solid composition of claim 45 wherein the total amount of desloratadine degradation products is no more than about 2.0 % by weight.

47) (New) The solid composition of claim 45 wherein a desloratadine-protective amount of a pharmaceutically acceptable binder is present in second layer.

48) (New) The solid composition of claim 45 wherein at least about 80% of the desloratadine dissolves in a 0.1N HCl solution at 37°C in about 45 minutes.

49) (New) The solid composition comprising a first and second layer wherein the first layer is an immediate release layer comprising:

<u>INGREDIENT</u>	<u>mg/composition</u>
Desloratadine, micronized	5.0
Corn Starch NF/Ph.Eur.	36.0
Microcrystalline Cellulose NF/Ph.Eur./JP	140.7
Edetate Disodium	10.0
Citric Acid	2.0
Talc USP/Ph.Eur.	6.0
Dye FD&C Blue No. 2 Aluminium Lake 5627	<u>0.30</u>
TOTAL	200.00

and wherein the second layer is a sustained release layer comprising:

<u>INGREDIENT</u>	<u>mg/composition</u>
Pseudoephedrine Sulfate USP	120.0
Hydroxypropyl Methylcellulose 2208, 1000,00cps	
USP/Ph.Eur.	105.0
Microcrystalline Cellulose NF/Ph.Eur./JP	103.5
Hydroxypropyl Methylcellulose 2910	10.5
Edetate Disodium	3.5
Silicon Dioxide NF	5.0
Magnesium Stearate NF/Ph.Eur.JP(Non-Bovine)	<u>2.5</u>
TOTAL	350.0

TOTAL Tablet Weight 550.0

wherein the total amount of desloratadine degradation products in the composition is less than or equal to about 2%.

50) (New) A solid composition comprising a first layer and a second layer, wherein the first layer is an immediate release first layer comprising:

<u>INGREDIENT</u>	<u>mg/composition</u>
Desloratadine, micronized	2.5
Corn Starch	18.0
Microcrystalline Cellulose	71.22

Edetate Disodium	5.0
Citric Acid	1.0
Talc	3.0
Dye FD+C Blue No. 2 Aluminium Lake	<u>0.28</u>
TOTAL	100.00

and wherein the second layer is an sustained release layer comprising:

<u>INGREDIENT</u>	<u>mg/composition</u>
Pseudoephedrine Sulfate	120.0
Hydroxypropyl Methylcellulose 2208	105.0
Microcrystalline cellulose	103.5
Edetate Disodium	3.5
Hydroxypropyl Methylcellulose 2910	10.5
Silicon Dioxide	5.0
Magnesium stearate	<u>2.0</u>
TOTAL	350.0

and wherein total amount of desloratadine degradation products is less than or equal to about 2% by weight .

51) (New) The solid composition of claim 50 wherein at least about 80% of the desloratadine dissolves in a 0.1N HCl solution at 37°C in about 45 minutes.

52) (New) A method of treating allergic and inflammatory conditions of the upper and lower airway passages and skin which comprises administering to a patient in need of such treating an effective amount of the composition of claims 42.

53) (New) A method of treating the signs and symptoms of nasal congestion associated with allergic and inflammatory conditions of the upper and lower airway passages and skin which comprises administering to a patient in need of such treating an effective amount of the composition of claim 42.

54) (New) A method of treating the signs and symptoms of nasal congestion associated with allergic and inflammatory conditions of the upper and lower airway passages and skin which comprises administering to a patient in need of such treating an effective amount of the composition of claim 44.

55) (New) A method of treating the signs and symptoms of nasal congestion associated with allergic and inflammatory conditions of the upper and lower airway passages and skin which comprises administering to a patient in need of such treating an effective amount of the composition of claim 45.

56) (New) A method of treating the signs and symptoms of nasal congestion associated with allergic and inflammatory conditions of the upper and lower airway passages and skin which comprises administering to a patient in need of such treating an effective amount of the composition of claim 50.

57) (New) A method of treating the signs and symptoms of urticaria which comprises administering to a patient in need of such treating an effective amount of the composition of claim 42.

58) (New) A method of treating the signs and symptoms of urticaria which comprises administering to a patient in need of such treating an effective amount of the composition of claim 44.

59) (New) A method of treating the signs and symptoms of urticaria which comprises administering to a patient in need of such treating an effective amount of the composition of claim 45.

60) (New) A method of treating the signs and symptoms of urticaria which comprises administering to a patient in need of such treating an effective amount of the composition of claim 49.

61) (New) A method of treating the signs and symptoms of urticaria which

comprises administering to a patient in need of such treating an effective amount of the composition of claim 50.

62) (New) A method of treating the nasal and non-nasal symptoms of perennial and seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the composition of claim 42.

63) (New) A method of treating the nasal and non-nasal symptoms of perennial and seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the composition of claim 44.

64) (New) A method of treating the nasal and non-nasal symptoms of perennial and seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the composition of claim 45.

65) (New) A method of treating the nasal and non-nasal symptoms of perennial and seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the composition of claim 49.

66) (New) A method of treating the nasal and non-nasal symptoms of perennial and seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the composition of claim 50.